Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension

Endocrine Journal

Volumn 60, Issue 5, 2013, Pages 563-570

  Arao, Tadashi ^a   Okada, Yosuke ^a   Mori, Hiroko ^a   Nishida, Keiko ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Anti inflammatory effect; Hs CRP; Hypertension; RAS; Type 2 Diabetes

Indexed keywords

ADIPONECTIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OLMESARTAN; PIOGLITAZONE; SULFONYLUREA DERIVATIVE; TELMISARTAN; TRIACYLGLYCEROL;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPID METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; C-REACTIVE PROTEIN; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG RESISTANCE; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; HYPOGLYCEMIC AGENTS; IMIDAZOLES; INSULIN RESISTANCE; MALE; MIDDLE AGED; TETRAZOLES;

EID: 84878492749     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ12-0326     Document Type: Article

References (32)

1. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, et al. (1998) Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS 23). BMJ 316: 823-828.
2. UKPDS Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: 703-713.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC7 report. JAMA 289: 2560-2572.
4. Hirose H, Saito I (2003) Trends in blood pressure control in hypertension patients with diabetes mellitus in Japan. Hypertentions Res 26: 717-722.
5. Zhang C, Hein TW, Wang W, Kou L (2003) Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res 92: 322-329.
6. Dzau VJ (2001) Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 37: 1047-1052.
7. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial aganst atenolol. Lancet 359: 995-1003.
8. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362: 759-766.
9. Nakayama S, Watada H, Mita T, Ikeda F, Shimizu T, et al. (2008) Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertensions Res 31: 7-13.
10. Sasaki T, Noda Y, Yasuoka Y, Irino H, Abe H, et al. (2008) Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose and lipid profiles with hypertension, chronic heart failure, and metabolic syndrome. Hypertensions Res 31: 921-929.
11. Mizuno M, Sada T, Ikeda M, Fukuda N, Miyamoto M, et al. (1995) Pharmacology of CS-866, a novel nonpeptide angiotensinn II receptor antagonist. Eur J Pharmacol 285: 181-188.
12. Burnier M, Brunner HR (2000) Angiotensin II receptor antagonists. Lancet 355: 637-645.
13. Chrysant SG, Chrysant GS, Desai A (2005) Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan. J Hum Hypertens 19: 173-183.
14. Kakuta H, Sudoh K, Sasamata M, Yamagishi S (2005) Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmcol Res 25: 41-46.
15. Fliser D, Buchholz K, Haller H (2004) Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110: 1103-1107.
16. Link A, Lenz M, Legner D, Böhm M, Nickenig G (2006) Telmisartan inhibits beta2-integrin MAC-1 expression in human T-lymphocytes. J Hypertens 24: 1891-1898.
17. Nagel JM, Tietz AB, Göke B, Parhofer KG (2006) The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism 55: 1149-1154.
18. Mori H, Okada Y, Arao T, Nishida K, Tanaka Y (2012) Telmisartan at 80 mg/day increases high-molecularweight adiponectin levels and improves insulin resistance in diabetic patients. Adv Ther 29: 635-644.
19. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, et al. (2004) Identification of telmisartan as a unique antagonist with selective PPARgannmamodulating activity. Hypertension 43: 993-1002.
20. Clemenz M, Frost N, Schupp M, Caron S, Foryst-Ludwig A, et al. (2008) Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan. Diabetes 57: 1405-1413.
21. Schupp M, Janke J, Clasen R, Unger T, Kintscher U (2004) Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109: 2054-2057.
22. Koike H, Konse T, Sada T, Ikeda T, Hyogo S, et al. (2003) Olmesartan medoxomil, a novel potent angiotensin II blocker. Annu Rep Sankyo Res Lab 55: 1-91.
23. Noda K, Saad Y, Kinoshita A, Boyle TP, Graham RM, et al. (1995) Tetrazole and carboxylase groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms. J Biol Chem 270: 2284-2289.
24. Takezako T, Gogonea C, Saad Y, Noda K, Karnik SS (2004) "Network leaning" as a mechanism of insurmountable antagonism of the angiotensinn II type 1 receptor by non-peptide antagonists. J Biol Chem 279: 15248-15257.
25. Igarashi M, Hirata A, Kadomoto Y, Tominaga M (2006) Dual blockade of angiotensin II with enalapril and losartan reduces proteinurea in hypertensive patients with type 2 diabetes. Endocr J 53: 493-501.
26. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, et al. (2000) A novel angiotensin-converting enzymerelated carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87: E1-9.
27. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, et al. (2003) Angiotensin-(1-7) is endogeneous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100: 8258-8263.
28. Agata J, Ura N, Yoshida H, Shinshi Y, Sasaki H, et al. (2006) Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res 29: 865-874.
29. Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, et al. (2003) Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 41: 392-397.
30. Wong DW, Oudit GY, Reich H, Kassiri Z, Zhou J, et al. (2007) Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol 171: 438-451.
31. Batll B, Soler MJ, Ye M (2010) ACE2 and diabetes: ACE of ACEs? Diabetes 59: 2994-2996.
32. Bindom SM, Hans CP, Xia H, Boulares AH, Lazartigues E (2010) Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice. Diabetes 59: 2540-2548.